Gottlieb worked for the U.S. Food and Drug Administration (FDA) from 2002 to 2003 and 2005 to 2007.[10] He first served as a senior advisor to the FDA Commissioner and then as the FDA's Director of Medical Policy Development from 2002 to 2003.[11] He helped initiate the FDA's generic drug user fee program and the Physician Labeling Rule. He worked on development of the FDA's policies related to the tentative approval of fixed-dose combination drugs for the treatment of HIV/AIDS under the PEPFAR program. He left the FDA in the spring of 2003 to become a senior advisor to the Administrator of the Centers for Medicare &Medicaid Services (CMS),where he worked on implementation of the Medicare Prescription Drug,Improvement,and Modernization Act (MMA),with its new Part D drug benefit,and helped advance the agency's coverage policies related to new medical technology.[12][13]
He returned to the FDA from 2005 to 2007 as the agency's Deputy Commissioner for Medical and Scientific Affairs,where he was appointed to the Senior Executive Service and granted a top secret security clearance. He was a member of the Biodefense Interagency Working Group to help draft a strategic plan for U.S. biodefense countermeasures. He also worked on advancing a framework for the creation of a generic drug user fee program,final implementation of the physician labelling and pregnancy labelling rules,and pandemic preparedness. In that latter role,Gottlieb recused himself from parts of the planning effort on a bird flu vaccine in 2005,because he had done consulting work for GSK,whose products might be used.[14]
Prior to becoming FDA Commissioner,Gottlieb testified about 20 times[17] before committees of the United States House of Representatives and the United States Senate on issues related to FDA regulation and drug competition,[18] drug shortages,[19][20] Medicare reimbursement and healthcare reform[21] and medical innovation.[22] During congressional investigations of the rise of the price of EpiPen,Gottlieb presented testimony arguing that the generic drug industry is burdened by regulation that slows the development and review of new generic drug applications. These regulations,he argued,made it especially hard to bring forward generic equivalents of complex drugs,including hard-to-formulate medicines and drugs coupled to a device delivery system—a category of medicines that includes EpiPen. He argued that such excessive regulations "undermine the competitive opportunities that could help inspire more choice and competition,and help lower costs."[18]
Gottlieb was an independent director at Tolero Pharmaceuticals[23] and Daiichi Sankyo Inc.[24] and a member of GlaxoSmithKline's product investment board,which made decisions on which drugs GSK would take forward in development.[25] He was a senior healthcare advisor to BDO and also a partner at a merchant bank with a focus on healthcare.[26] In 2015,he served on the board one of the investment firm's portfolio companies that was a provider of vaping products,Kure Corp.[27] During this time,Gottlieb was a regular contributor to the Wall Street Journal editorial page and published a regular feature in Forbes related to healthcare and medical innovation,[28] and he served on the editorial board of the Food and Drug Law Institute's publication entitled Food and Drug Policy Forum that "provides for the exchange of ideas and recommendations on state,national,and international food and drug law and policy issues" and serves as a forum for discussion of regulatory policy in the food,drug,and medical device industry.[11][29][30]
FDA commissioner (2017–2019)
Gottlieb speaks at the National Press Club in 2017
Starting in summer 2016,Gottlieb worked as an advisor to Donald Trump's presidential campaign,and then as a member of his transition team. He previously advised the 2016 presidential campaign of Wisconsin Governor Scott Walker.[31]
As Commissioner,Gottlieb displayed "a collaborative management style,seeming to allay the concerns of some career employees who had balked at his industry ties," according to The New York Times.[43] While Commissioner,Gottlieb testified before Congress 19 times.[44]
On June 8,2017,Gottlieb requested[45] the market withdrawal of the opioid Opana ER,based on a risk associated with the illicit use of the product when the drug was inappropriately reformulated for abuse through injection. It was the first time the FDA sought to withdraw a product based on a risk associated entirely with the illicit use of a medical product.[46]
On July 28,2017,Gottlieb delayed application deadlines on new tobacco products,including premium cigars and electronic cigarettes,to provide sufficient time to finalize regulations on how those products would be regulated by the FDA,and at the same time,announced that the FDA would take steps to regulate nicotine levels in combustible cigarettes to render the combustible cigarettes "minimally or non-addictive," and to regulate flavored tobacco products,including menthol cigarettes.[47][48] The announcement caused shares of tobacco company Altria that day to initially decline by 19%.[49]
In December 2017,Gottlieb unveiled a policy to step up FDA's oversight of homeopathic drugs,which had previously gone largely unregulated. At the same time,the FDA issued a series of warning letters seeking to remove certain unsafe and violative homeopathic products from the market.[52]
In March 2018,the FDA,under Gottlieb,initiated a rule to lower the amount of nicotine in cigarettes to make them less addictive—in "an unprecedented move by the agency…It's the boldest move yet against cigarette makers by the FDA,which only obtained permission to regulate tobacco products in 2009."[53][54][55][56]
In August 2017,Gottlieb announced an initiative to accelerate the development of cell based therapies while also taking actions to crack down on what he called "unscrupulous" actors who were marketing unregulated stem cell therapy products that had caused some patients harm. Many of the companies that the FDA cited had been performing liposuction to remove fat from patients,isolating stem cells and then injecting those cells back into the same patients to treat various ailments.[57] In May 2018,Gottlieb asked federal courts on opposite sides of the country to permanently stop two stem cell companies from operating after reports of patients being blinded by their treatments and released new guidelines on how the FDA would set enforcement priorities.[58]
Gottlieb also announced an initiative to accelerate development of FDA regulated cell and gene therapies in anticipation of a surge of new applications for commercial products. Among other things,Gottlieb said the FDA would add 50 additional reviewers to its staff,and issue new guidance documents that would lay out the pathway for development of different kinds of products such as gene therapies for inherited blood disorders and neurodegenerative diseases.[59]
In September 2018,citing an epidemic of use of electronic cigarettes by teenagers,Gottlieb announced that the FDA would seek to ban flavors in e-cigs as a way to reduce their appeal to youth.[60] On November 8,2018,it was reported that the FDA was "expected to announce a ban on the sale of most flavored e-cigarettes in tens of thousands of convenience stores and gas stations across the country",according to senior agency officials,and "the agency will also impose such rules as age-verification requirements for online sales." The reports noted that "Gottlieb also is expected to propose banning menthol in regular cigarettes. The agency has been collecting public comments on such a prohibition,which is a major goal of the public health community but is likely to be strongly opposed by the cigarette industry." It was also reported that Gottlieb would seek to ban flavors in cigars.[61] Gottlieb stated,"I will not allow a generation of children to become addicted to nicotine through e-cigarettes." with The Washington Post editorializing that the new rules "represent an extraordinary step in the fight against nicotine addiction,one that,if successful,would become one of the nation's greatest public-health victories."[62] That policy was formally unveiled in March 2019. Gottlieb also called into question the motives behind the decision by Altria to take a minority stake in Juul and accused the manufacturer of reneging on commitments and representations it had made to FDA.[63]
Gottlieb pursued policies to address barriers to the approval of complex generic drugs,including generic,functionally equivalent alternatives to EpiPen.[64][65][66] Under his leadership,in August 2018,the FDA approved the first generic competitor of EpiPen,[67] and later,in January 2019,the agency approved a generic competitor to the asthma drug Advair. Of the agency's more than 1,000 generic approvals in 2018,about 14 percent were for "complex generic drugs," or drugs that are particularly difficult to "genericize."[68]
In November 2018,the FDA implemented a new framework,in collaboration with the Department of Defense,to expedite the development of medical products intended to support American soldiers on the battlefield.[69] Gottlieb had fought to maintain FDA control over the review and approval of medical products intended to support the war fighter after the Pentagon had sought to acquire that authority for itself as part of the National Defense Authorization Act. "I'm fully committed to trying to expedite products for the war fighter,and ... if they pass the language that has been put forward —the alternative language —we will commit to very quickly putting in place the implementing guidance to stand up that process," Gottlieb said as the Pentagon's version of the provision was moving through the House and the Senate. Ultimately,the compromise was to retain the authority with the FDA but for the FDA to commit to offer products intended for the battlefield a higher priority of review,reflecting the compromise provision that Gottlieb had put forward.[70][71] The episode exposed an unusual "turf war" that pitted Gottlieb and the FDA against Pentagon officials[72] and "puts on public display an internal rift within the administration and in Republican congressional ranks."[73]
Gottlieb advanced initiatives on addressing drug pricing,[74] "in ways that the agency hasn't done before."[75] In December 2018,Gottlieb announced a plan to transition the biologicals currently regulated as drugs,including insulin,to be regulated under the Public Health Services Act as a way to open up these drugs to competition from lower cost biosimilars.[76]
He also committed to make fighting opioid addiction one of his highest priorities as Commissioner.[77] He announced that the FDA would pursue a comparative approval standard[78] for new opioids seeking to come to market,arguing that new opioid painkillers should show advantages over existing opioid drugs to win FDA approval. He undertook a series of new steps to rationalize prescribing as a way to reduce exposure to opioid drugs in order to cut the rate of new addiction.[79] Under Gottlieb's leadership,"The FDA stirred up a hornet's nest with an unprecedented request to Endo International to remove voluntarily its opioid pain medication,a tamper-resistant reformulation of Opana ER (oxymorphone hydrochloride),from the market."[80]
In February 2019,Gottlieb took action to curtail the marketing of 17 dietary supplements that were making unlawful and unproven medical claims to treat Alzheimer's disease and,at the same time,unveiled a set of policy steps to strengthen the FDA's oversight of dietary supplements that was billed as the most significant modernization of the agency's regulation of supplements in 25 years.[81]
In Spring 2019,Gottlieb took a series of actions to create a new framework for the development and FDA oversight of artificial intelligence medical devices. The stated goal was to allow products that sought to make regulated medical claims to come to the market through a predictable,negotiable regulatory process.[82][83]
In March 2019,Gottlieb pressed for the market withdrawal of certain cosmetics because they were found to contain asbestos,at the same time that he announced a set of new proposals to strengthen oversight of the cosmetics industry,winning praise from legislators who had been pressing for similar reforms.[84]
On March 5,2019,Gottlieb announced his resignation as FDA Commissioner,effective in about a month. He said that he wanted to spend more time with his family.[85][86][87] At the time of his resignation,Politico observed,"FDA leaders have typically focused much of their attention on a handful of medical topics,but Gottlieb has been active and aggressive on many issues as commissioner without hewing to a strictly conservative or liberal ideology. It's an approach that's won him praise from many in the health sector,while garnering criticism from several of the targeted businesses like tobacco companies and the fast-growing e-cigarette industries."[88]
Gottlieb was called "an unusually activist regulator in the Trump administration whose agenda touched everything from tobacco to trans-fats," and he "wasn't afraid to speak on topics normally seen as a third rail for a FDA commissioner,including drug pricing…His most high-profile advocacy came in the area of youth smoking,where he aggressively pressed e-cigarette manufacturers and retailers to halt marketing to teens."[89] At the same time,other reports observed that Gottlieb left the FDA with some of his signature tobacco policies still awaiting full implementation,including his plans to ban menthol in cigarettes.[90]
On March 13,2019,Gottlieb moved to restrict sales of flavored e-cigarettes to try to reduce the soaring rate of teenage vaping. The agency issued a proposal requiring that stores sequester flavored e-cigarettes to areas off-limits to anyone under age 18. The proposal also called for banning the sale of many flavored cigars.[91] Under the policy,the FDA would reserve the right to push companies to comply or remove their products from shelves.
On March 27,2019,Gottlieb advanced a new federal rule stipulating,for the first time,that centers that provide mammograms to screen for breast cancer will have to tell women whether they have dense breast tissue,which can increase the risk of cancer and mask tumors. The rule marked the first changes proposed in 20 years to the FDA's regulations on mammography.[92][93]
While commissioner,Gottlieb undertook a substantial expansion of the FDA's interdiction activities inside the international mail facilities,to expand the agency's ability to intercept opioids being shipped through the mail from places like China. He sought and received money from Congress to hire dozens of more staff to inspect 100,000 packages per year that had been flagged as suspicious by customs agents,up from a prior capacity of roughly 40,000.[94] The FDA also launched a new collaboration with Customs and Border Protection to step up joint inspectional activities.[95][96][97]
Private sector (2019–present)
Upon leaving the FDA,Gottlieb returned to the American Enterprise Institute.[98][99] In May 2019,he returned to New Enterprise Associates as a partner in the firm's healthcare practice,and joined the board of two NEA portfolio companies,Aetion,Inc. and Tempus.[1][2][100] Gottlieb was elected as an independent member of the board of directors of Pfizer,Inc. in June 2019.[101][102] He joined the Illumina,Inc. board of directors in February 2020[4] and the National Resilience,Inc. board of directors in November 2020,where he was one of the original venture investors.[103][104] He is also a member of the boards of trustees of the Mount Sinai Health System[105] and Wesleyan University.[106] Gottlieb is a regular contributor to the Journal of the American Medical Association's Health Forum.
With the advent of the COVID-19 reaching the United States and a great deal of misinformation being presented or correct information not being presented,Gottlieb has spoken out with public information on the virus on many venues.[107][108][109] On February 12,2020,Gottlieb testified before the Senate Committee on Homeland Security and Governmental Affairs on preparedness for the novel coronavirus and future pandemic threats.[110][111] On March 29,2020,Gottlieb and several public health experts published "National Coronavirus Response:A Road Map to Reopening",providing specific actions for navigating through the current COVID-19 pandemic in the United States.[112] Since April 2020,Gottlieb has advised several governors on the COVID-19 pandemic. He joined Maryland GovernorLarry Hogan's COVID-19 response team and Massachusetts GovernorCharlie Baker's COVID-19 advisory board.[113] He has also advised Connecticut GovernorNed Lamont as a member of the Reopen Connecticut Advisory Group.[114] On November 20,2020,it was announced that Gottlieb would serve on Montana's Governor-elect Greg Gianforte's COVID-19 task force.[115] Gottlieb was criticized by Substack author Alex Berenson for contacting Twitter;Berenson alleged it was to get him removed from the platform.[116]
Gottlieb was a staff writer of the British Medical Journal (The BMJ) from 1997 to 2005 and a senior editor of the Pulse section of the Journal of the American Medical Association (JAMA) from 1996 to 2001.[122] He is a regular contributor to the editorial page of The Wall Street Journal and The Washington Post and wrote regularly for Forbes.[123] In 2020 and 2021,Gottlieb authored a weekly column for the editorial page of the Wall Street Journal.[124] Many of his articles have addressed the intersection of public policy and the practice of medicine. Gottlieb was a frequent and early critic of the Patient Protection and Affordable Care Act.[125] He wrote an editorial in The Wall Street Journal,on the day of the health plan's launch,predicting the ensuing problems with the healthcare.gov website.[126] Gottlieb argued that studies showed some patients who received Medicaid had worse outcomes,including death,when they had certain conditions like head and neck cancer,compared to patients who had no insurance coverage at all. He observed that in these cases,uninsured patients had access to newer medicines through free patient assistance programs,whereas federal law prevented Medicaid patients from getting access to these free drug programs because they were enrolled in Medicaid. As a result,Medicaid patients depended on whether or not these newer and typically costlier medicines were covered by their state Medicaid programs,which,in the cases Gottlieb cited,were not available.[127] Critics said that his article was based on "a classic misunderstanding:confusing correlation for causation," a limitation explicitly mentioned in papers he cited.[128][129][130]
In October 2019,Gottlieb wrote a feature for the conservative editorial page of The Wall Street Journal,where he called for a "reckoning" when it comes to the impasse between state laws legalizing cannabis and the policy of federal prohibition that outlaws cannabis but is largely unenforced. In that op-ed,Gottlieb called for a pathway toward federal legalization of cannabis that would allow,among other reforms,easier access to the compound for research while exerting stricter and more uniform regulation over products.[131][132] In a separate editorial writing in The Washington Post,Gottlieb called on Congress and the FDA to create a framework for the legal sale of regulated CBD.[133]
In January 2020,Gottlieb wrote several articles warning about the spread of COVID-19 in the United States. On January 23,Gottlieb wrote an Op-Ed titled "What must be done to head off the coronavirus threat" in The Washington Post.[134] On January 27,Gottlieb wrote an Op-Ed titled "We need to prepare for US outbreak of Wuhan coronavirus."[135] and on January 28,Gottlieb and Luciana Borio wrote an opinion which appeared in the editorial opinion of The Wall Street Journal entitled "Act Now to Prevent an American Epidemic."[136]
Gottlieb examined the systemic shortcomings of the U.S. response to the COVID-19 pandemic in his new book, Uncontrolled Spread:Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic, which was released on September 21,2021 by HarperCollins.[137]Uncontrolled Spread debuted at No.5 on The New York Times Best Seller list for Hardcover Nonfiction and at No.6 for Combined Print &E-Book Nonfiction.[138][139] The book also debuted at No.9 on The Wall Street Journal Best Seller list for Hardcover Nonfiction and No.8 on the Publishers Weekly hardcover Nonfiction Best Seller list.[140]
Recognition
Fortune magazine identified Gottlieb as one of its 2018 "The World's 50 Greatest Leaders," ranking him number 6. The magazine stated "Gottlieb has gotten credit for being transparent about FDA steps—and,more important,for using his bully pulpit without being a bully."[141]Fortune magazine selected Gottlieb again in its 2019 survey,ranking him number 50 among its "World's 50 Greatest Leaders."[142]
Time magazine named Gottlieb one of its "50 People Transforming Healthcare in 2018,"[143] noting that "Gottlieb gained supporters for grounding his tough policies in scientific evidence."
In naming Gottlieb as one of its "50 Politicos for 2018," the publication Politico noted that "This isn't the Scott Gottlieb many people had expected. As a Bush administration official,the physician was an avowed free-marketer,leading liberals to worry he would aggressively try to dismantle the FDA's vast regulatory apparatus. But since his confirmation,as counterparts at other federal agencies have focused on overturning or undermining the rules they inherited,Gottlieb has struck a genuine balance at the FDA."[144]
In naming Gottlieb the "Most Influential Physician Executive and Leader" in its 2018 annual survey of 50 physician executives,Modern Healthcare noted that "an unprecedented level of transparency and public disclosure has garnered support from across the industry."[145] In 2019,Modern Healthcare again named Gottlieb the most influential physician executive and leader,noting "Gottlieb accomplished a rare feat during his two-year tenure as head of the Food and Drug Administration—he earned praise from Republicans and Democrats alike." Modern Healthcare observed "although he stepped down in April,stakeholders hope the former commissioner's endeavors will live on and influence future agency heads."[146]
Modern Healthcare also named Gottlieb nineteenth in its survey of the 100 most influential people in healthcare,in 2018,[147] fifty-fifth in 2019,and fifty-fourth in 2021.[148][149]
In May 2019,Gottlieb received an honorary Doctor of Science degree from the Icahn School of Medicine at Mount Sinai for "his commitment to improving the nation's health and for his work at the FDA,expediting the approval of treatments and drugs,and battling opioid addiction and the use of e-cigarettes by youth."[152]
In September 2019,Gottlieb received Cancer Research Leadership Award from Friends of Cancer Research in recognition of his leadership in the regulatory and scientific innovations.[153]
Gottlieb was recognized on Modern Healthcare's list of 50 Most Influential Clinical Executives for 2020. The magazine stated that Gottlieb "has maintained a high—and influential—profile. During the COVID-19 pandemic,he has been active in the media—both traditional and social—talking about a host of challenges facing the nation,from the supply chain to the importance of a test-trace-isolate protocol."[154]
Medical Marketing &Media (MM&M) and PRWeek recognized Gottlieb on their 2020 Health Influencer 50 list,ranking him number 4. They noted that "In a year that will likely be remembered for medical misinformation and the proliferation of science-deniers,Dr. Scott Gottlieb continues to stand out as one of the clearest and most direct communicators of all things health-related."[155]
Gottlieb was named one of "Washington's 2021 Most Influential People" by Washingtonian.[156]
In May 2021,Gottlieb received an honorary Doctor of Science degree from Wesleyan University in recognition of "his achievements in dealing with the opioid crisis,the epidemic use of electronic cigarettes,and drug pricing,as well as his willingness to speak up and educate others on the nature of the COVID-19 virus."[157] In 2022,he was inducted into the East Brunswick High School "Hall of Fame," where he [158]graduated in 1990.
Gottlieb was recognized by Modern Healthcare as one of 2021's 100 Most Influential People in Healthcare.[159]
Mediaite recognized Gottlieb on their Most Influential in News Media 2021 list,ranking him number 24. They noted that Gottlieb "established himself as one of the most valuable experts to follow on the Covid-19 pandemic in 2021. Gottlieb's regular appearances on the CBS Sunday show Face the Nation,as well as CNBC's Squawk Box,were refreshing in their honesty and sharp analysis. Unlike many in the Covid pundit class,Gottlieb did not shy away from challenging orthodoxy. He also called out both sides of the aisle,blaming his former boss for politicizing Covid while blaming the Biden administration for its mixed messaging surrounding the pandemic."[160]
Gottlieb was named one of Washington,D.C.'s 500 Most Influential People Shaping Policy in 2022 and 2023 by Washingtonian.[161][162]
FiercePharma named Gottlieb one of "The 22 most influential people in the fight against COVID-19," noting that Gottlieb "emerged as an important and trusted voice" and "Through the pandemic,Gottlieb has been a vocal advocate of science and an eager educator explaining complex concepts about the virus,vaccines and treatments."[163]
The United States Food and Drug Administration is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety,tobacco products,caffeine products,dietary supplements,prescription and over-the-counter pharmaceutical drugs (medications),vaccines,biopharmaceuticals,blood transfusions,medical devices,electromagnetic radiation emitting devices (ERED),cosmetics,animal foods &feed and veterinary products.
Mitragyna speciosa is a tropical evergreen tree in the coffee family native to Southeast Asia. It is indigenous to Thailand,Indonesia,Malaysia,Myanmar,and Papua New Guinea,where it has been used in herbal medicine since at least the 19th century. It has also historically been used for chewing,smoking,and tea. Kratom has opiate properties and some stimulant-like effects.
Cardinal Health,Inc. is an American multinational health care services company,and the 14th highest revenue generating company in the United States. Headquartered in Dublin,Ohio,the company specializes in the distribution of pharmaceuticals and medical products,serving more than 100,000 locations. The company also manufactures medical and surgical products,including gloves,surgical apparel,and fluid management products. In addition,it operates one of the largest networks of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States.
An electronic cigarette (e-cigarette) or vape is a device that simulates tobacco smoking. It consists of an atomizer,a power source such as a battery,and a container such as a cartridge or tank filled with liquid. Instead of smoke,the user inhales vapor. As such,using an e-cigarette is often called "vaping". The atomizer is a heating element that vaporizes a liquid solution called e-liquid,which quickly cools into an aerosol of tiny droplets,vapor and air. E-cigarettes are activated by taking a puff or pressing a button. Some look like traditional cigarettes,and most kinds are reusable. The vapor mainly comprises propylene glycol and/or glycerin,usually with nicotine and flavoring. Its exact composition varies,and depends on several things including user behavior.
Hash oil or cannabis oil is an oleoresin obtained by the extraction of cannabis or hashish. It is a cannabis concentrate containing many of its resins and terpenes –in particular,tetrahydrocannabinol (THC),cannabidiol (CBD),and other cannabinoids. Hash oil is usually consumed by smoking,vaporizing or eating. Preparations of hash oil may be solid or colloidal depending on both production method and temperature and are usually identified by their appearance or characteristics. Color most commonly ranges from transparent golden or light brown,to tan or black. There are various extraction methods,most involving a solvent,such as butane or ethanol.
Regulation of electronic cigarettes varies across countries and states,ranging from no regulation to banning them entirely. As of 2015,around two thirds of major nations have regulated e-cigarettes in some way.
blu is an electronic cigarette brand,produced by Fontem Ventures and owned by Imperial Brands. The brand blu sells various types of rechargeable and disposable e-cigarettes with a wide selection of flavored and unflavored liquids. Its products are available in many countries and each market offers different types of products suited to public demand and opportunities. The global headquarters of blu is located in Amsterdam. Local offices are active around the world to service all markets which sell the brand.
The use of electronic cigarettes (vaping) carries health risks. The risk depends on the fluid and varies according to design and user behavior. In the United Kingdom,vaping is considered by some to be around 95% less harmful than tobacco after a controversial landmark review by Public Health England.
The scientific community in the United States and Europe are primarily concerned with the possible effect of electronic cigarette use on public health. There is concern among public health experts that e-cigarettes could renormalize smoking,weaken measures to control tobacco,and serve as a gateway for smoking among youth. The public health community is divided over whether to support e-cigarettes,because their safety and efficacy for quitting smoking is unclear. Many in the public health community acknowledge the potential for their quitting smoking and decreasing harm benefits,but there remains a concern over their long-term safety and potential for a new era of users to get addicted to nicotine and then tobacco. There is concern among tobacco control academics and advocates that prevalent universal vaping "will bring its own distinct but as yet unknown health risks in the same way tobacco smoking did,as a result of chronic exposure",among other things.
Robert McKinnon Califf is an American cardiologist who currently serves as the 25th Commissioner of the Food and Drug Administration.
A vape shop is a retail outlet specializing in the selling of vaping products,though shops selling derived psychoactive cannabis products have increased since the passage of the 2018 Farm Bill. There are also online vape shops. A vape shop offers a range of vaping products. The majority of vape shops do not sell vaping products that are from "Big Tobacco" companies. In 2013,online search engine searches on vape shops surpassed searches on e-cigarettes. Around a third of all sales of vaping products take place in vape shops. Big Tobacco believes the independent vape market is a threat to their interests.
Juul Labs,Inc. is an American electronic cigarette company that spun off from Pax Labs in 2017. Juul Labs makes the Juul electronic cigarette,which atomizes nicotine salts derived from tobacco supplied by one-time use cartridges.
NJOY,LLC is an American company that manufactures and distributes electronic cigarettes and vaping products. In 2017,NJOY acquired the assets of NJOY,Inc.,one of the first companies to sell e-cigarettes. On June 1,2023,the company was acquired by Altria Group.
In the United States,the opioid epidemic is an extensive,ongoing overuse of opioid medications,both from medical prescriptions and illegal sources. The epidemic began in the United States in the late 1990s,according to the Centers for Disease Control and Prevention (CDC),when opioids were increasingly prescribed for pain management,resulting in a rise in overall opioid use throughout subsequent years. The great majority of Americans who use prescription opioids do not believe that they are misusing them.
Janet Woodcock is an American physician serving as Principal Deputy Commissioner of Food and Drugs,having previously served as Acting Commissioner of the U.S. Food and Drug Administration (FDA). She joined the FDA in 1986,and has held a number of senior leadership positions there,including terms as the Director of Center for Drug Evaluation and Research (CDER) from 1994 to 2004 and 2007 to 2021.
An outbreak of e-cigarette,or vaping,product use-associated lung injury (EVALI) started in 2019 among users of illegal,unregulated cannabis vaping products,almost exclusively in the United States. The first cases of this particular outbreak were identified in Illinois and Wisconsin in April 2019;as of 18 February 2020,a total of 2,807 hospitalized cases,including 68 deaths,have been confirmed. According to the U.S. Centers for Disease Control (CDC),"Vitamin E acetate is strongly linked to the EVALI outbreak...Evidence is not sufficient to rule out the contribution of other chemicals of concern,including chemicals in either THC or non-THC products,in some of the reported EVALI cases".
Vaping-associated pulmonary injury (VAPI),also known as vaping-associated lung injury (VALI) or e-cigarette,or vaping,product use associated lung injury (E/VALI),is an umbrella term,used to describe lung diseases associated with the use of vaping products that can be severe and life-threatening. Symptoms can initially mimic common pulmonary diagnoses,such as pneumonia,but sufferers typically do not respond to antibiotic therapy. Differential diagnoses have overlapping features with VAPI,including COVID-19. According to a systematic review article,"Initial case reports of vaping-related lung injury date back to 2012,but the ongoing outbreak of EVALI began in the summer of 2019." According to an article in the Radiological Society of North America news published in March 2022,EVALI cases continue to be diagnosed. “EVALI has by no means disappeared,”Dr. Kligerman said. “We continue to see numerous cases,even during the pandemic,many of which are initially misdiagnosed as COVID-19.”
Electronic cigarettes are marketed to smoking and non-smoking men,women,and children as being safer than cigarettes. In the 2010s,large tobacco businesses accelerated their marketing spending on vape products,similar to the strategies traditional cigarette companies used in the 1950s and 1960s.
Vin Gupta is an American pulmonologist who is a medical analyst for NBC News and MSNBC. He also serves as a senior principal scientist with Amazon,affiliate professor with the University of Washington's Institute for Health Metrics and Evaluation,attending physician at Virginia Mason Medical Center,and lead officer of the Critical Care Air Transport Team for the United States Air Force Medical Service Reserves,based at Joint Base Lewis–McChord.
Brian King is an American Epidemiologist who currently serves as the Director of the Food and Drug Administration’s Center for Tobacco Products (CTP). He was appointed to his role in July 2022.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
